FDAs 2026 BPC-157 briefing document also described a spontaneous adverse-event report involving a product labelled BPC-157 plus TB-500
If your inflammation has a different root cause, it should not be treated as a one-size-fits-all answer
If youre a sugar producer and want to learn more about ethanol, sustainable aviation fuel, or even things like bioplastics, and how they can diversify your revenue away from sugar, please contact us
Our relationship with our patients extends far beyond the treatment room
Emerging preclinical and clinical evidence suggests that GIPR agonism can play a role in reducing the GI AEs of GLP-1R agonism and enable greater therapeutic potential
Published meta-analyses show berberine reduces fasting blood glucose by roughly 1015 mg/dL and HbA1c by 0.50.6% in people with type 2 diabetes or metabolic syndrome (Liang et al., 2019